| 来源类型 | Working Paper |
| 规范类型 | 报告 |
| DOI | 10.3386/w8482 |
| 来源ID | Working Paper 8482 |
| Pharmaceutical Prices and Political Activity | |
| Sara Fisher Ellison; Catherine Wolfram | |
| 发表日期 | 2001-09-01 |
| 出版年 | 2001 |
| 语种 | 英语 |
| 摘要 | Drug prices have been a conspicuous political issue in much of recent history, but no more so than during health care reform debates in 1993 and 1994. This paper investigates possible effects of political activity on pharmaceutical prices, with a particular focus on the health care reform period. It evaluates the extent to which pharmaceutical companies slowed the rates at which they increased prices in an attempt to preempt government intervention. To do so, we characterize companies based on their vulnerability to future price regulation. We then consider patterns in price movements across companies. The results suggest that companies whose drugs had longer patent lives and who had recently increased contributions to their corporate Political Action Committees (PACs) slowed price increases during 1992 and 1994 more than their competitors. It is difficult to distinguish pricing differences across companies in 1993, perhaps because most companies had pledged to keep price increases below the rate of inflation. |
| 主题 | Industrial Organization ; Regulatory Economics ; Industry Studies |
| URL | https://www.nber.org/papers/w8482 |
| 来源智库 | National Bureau of Economic Research (United States) |
| 引用统计 | |
| 资源类型 | 智库出版物 |
| 条目标识符 | http://119.78.100.153/handle/2XGU8XDN/566086 |
| 推荐引用方式 GB/T 7714 | Sara Fisher Ellison,Catherine Wolfram. Pharmaceutical Prices and Political Activity. 2001. |
| 条目包含的文件 | ||||||
| 文件名称/大小 | 资源类型 | 版本类型 | 开放类型 | 使用许可 | ||
| w8482.pdf（181KB） | 智库出版物 | 限制开放 | CC BY-NC-SA | 浏览 | ||
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
